Self-stigmatization and treatment preferences: Measuring the impact of treatment labels on choices for depression medications
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0309562 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Juan Marcos Gonzalez Sepulveda und 5 weiteren Autor:innen. Beteiligte Einrichtung: Duke Clinical Research Institute, Duke University School of Medicine Durham, North Carolina, United States of America. Hauptthemen laut MEDLINE: Antidepressive Agents, Major Depressive Disorder, Patient Preference, Choice Behavior. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Otsuka Pharmaceutical Development & Commercialization, Inc, Lundbeck, LLC.
Themen: Depression
Abstract (Originalsprache)
Objective
To collect evidence on the possibility that patients with depression experience self-stigmatization based on label information for medications.
Methods
We developed a discrete-choice experiment (DCE) survey instrument that asked respondents to make choices between hypothetical treatments for major depressive disorder (MDD). We also included treatment type (antidepressants versus antipsychotics) and approved indications for the medication. The choice questions mimicked the information presented in product inserts and required systematic tradeoffs between treatment efficacy, treatment type, and indication. We calculated how many patients were willing to forgo efficacy to avoid treatments with information associated with self-stigmatization, and how much efficacy they were willing to forgo. We also evaluated the impact of contextualizing the treatment information to reduce self-stigmatization by randomizing respondents who received additional context.
Results
A total of 501 patients with MDD were recruited to complete the DCE survey. Respondents had well-defined preferences for treatment outcomes. Over 60% (63.4%) of respondents were found to be significantly affected by treatment indication. These respondents were willing to forgo about 2.5 percentage points in the chance of treatment efficacy to avoid treatments indicated for schizophrenia. We also find that some level of contextualization of the treatment details could help reduce the negative impact of treatment type and indications.
Conclusions
Product-label treatment indication can potentially lead to patient self-stigmatization as shown by patients’ avoidance of treatments that are also used to treat schizophrenia. While the effect appears to be relatively small, results suggests that the issue is likely pervasive.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Duke Clinical Research Institute, Duke University School of Medicine Durham, North Carolina, United States of America.
- LCSW Gateway Counseling Center, Smithtown, New York, United States of America.
- Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ, United States of America.
ORCID-Profile: Juan Marcos Gonzalez Sepulveda
Förderung
- Otsuka Pharmaceutical Development & Commercialization, Inc
- Lundbeck, LLC
Zitieren
APA
Gonzalez Sepulveda, J. M., Townsend, M., Waters, H. C., Brubaker, M., Wallace, M., & Johnson, R. (2024). Self-stigmatization and treatment preferences: Measuring the impact of treatment labels on choices for depression medications. PLOS ONE. https://doi.org/10.1371/journal.pone.0309562
Vancouver
Gonzalez Sepulveda JM, Townsend M, Waters HC, Brubaker M, Wallace M, Johnson R. Self-stigmatization and treatment preferences: Measuring the impact of treatment labels on choices for depression medications. PLOS ONE. 2024. doi:10.1371/journal.pone.0309562
BibTeX
@article{GonzalezSepulveda2024,
author = {Gonzalez Sepulveda, Juan Marcos and Townsend, Michael and Waters, Heidi C and Brubaker, Maalak and Wallace, Matthew and Johnson, Reed},
title = {Self-stigmatization and treatment preferences: Measuring the impact of treatment labels on choices for depression medications},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0309562}
}
EUVIMED